SynthesisCancer cell2017
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.
Abstract readMeta-Analysis
In one paragraph
Synthesis in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 741 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
741citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
741 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Systemic versus intracranial immunotherapy delivery in pediatric malignant brain tumors: a systematic review, meta-analysis, and meta-regression.European journal of pediatrics · 2026Pooled it
- A systematic study of molecular diagnosis, treatment, and prognosis in infant-type hemispheric glioma: An individual patient data meta-analysis of 164 patients.Neuro-oncology · 2026Pooled it
- Machine learning in neuroimaging for predicting H3K27M mutations in diffuse midline gliomas: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Efficacy and safety of immunotherapy in pediatric malignant brain tumors: a systematic review and exploratory meta-analysis.Frontiers in oncology · 2026Pooled it
- Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.Nature medicine · 2026Trial
- Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group study.Neuro-oncology · 2025Trial
- Practical management of BRAF inhibitors in glioma: toxicity and resistance.CNS oncology · 2026Review
- Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma.Nature medicine · 2026Article
- MAPK-driven glioma progression and reprogramming of the tumor-associated immune response.Neuro-oncology · 2026Article
- The clinical and molecular landscape of thalamic glioma.Neuro-oncology · 2026Article
- The DIPG/DMG National Tumor Board: The power of advocacy.Neuro-oncology pediatrics · 2026Article
- Machine learning and computational approaches to model therapeutic response and resistance in diffuse midline glioma.Journal of neuro-oncology · 2026Review
- Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.Molecular therapy. Oncology · 2026Article
- Oncolytic viruses enhance CAR-T activity for the treatment of pediatric diffuse midline gliomas.Molecular therapy. Oncology · 2026Article
- CNS distribution and preclinical activity of the PI3K/AKT inhibitors inavolisib and ipatasertib in pediatric-type diffuse high-grade gliomas.Cancer chemotherapy and pharmacology · 2026Article
- Article
- Oncohistone inhibition reshapes tumor-microenvironment communication in Diffuse Midline Glioma (DMG).bioRxiv : the preprint server for biology · 2026Article
- Review
- Exon-skipping antisense oligonucleotides for H3.3K27M-altered diffuse midline glioma therapy.Molecular therapy. Nucleic acids · 2026Article
- Understanding DMG: current treatment options and prospective solutions using nanoparticles.Drug delivery and translational research · 2026Review
681 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
63 authors.
Alan MackayDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Anna BurfordDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Diana CarvalhoDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Elisa IzquierdoDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Janat Fazal-SalomDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Kathryn R TaylorDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK; Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
Lynn BjerkeDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Matthew ClarkeDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Mara VinciDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Meera NandhabalanDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Sara TemelsoDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Sergey PopovDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK; Department of Cellular Pathology, University Hospital of Wales, Cardiff, UK.
Valeria MolinariDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Pichai RamanThe Center for Data Driven Discovery in Biomedicine (D(3)b), Children's Hospital of Philadelphia, Philadelphia, PA, USA; Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Angela J WaandersThe Center for Data Driven Discovery in Biomedicine (D(3)b), Children's Hospital of Philadelphia, Philadelphia, PA, USA; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Harry J HanThe Center for Data Driven Discovery in Biomedicine (D(3)b), Children's Hospital of Philadelphia, Philadelphia, PA, USA; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Saumya GuptaInstitute of Molecular Life Sciences, Swiss Institute of Bioinformatics, University of Zürich, Zürich, Switzerland.
Lynley MarshallPediatric Oncology Drug Development Team, Children and Young People's Unit, Royal Marsden Hospital, Sutton, UK.
Stergios ZacharoulisPediatric Oncology Drug Development Team, Children and Young People's Unit, Royal Marsden Hospital, Sutton, UK.
Sucheta VaidyaPediatric Oncology Drug Development Team, Children and Young People's Unit, Royal Marsden Hospital, Sutton, UK.
Henry C MandevilleDepartment of Radiotherapy, Royal Marsden Hospital, Sutton, UK.
Leslie R BridgesDepartment of Cellular Pathology, St George's Hospital NHS Trust, London, UK.
Andrew J MartinDepartment of Neurosurgery, St George's Hospital NHS Trust, London, UK.
Safa Al-SarrajDepartment of Neuropathology, Kings College Hospital, London, UK.
Christopher ChandlerDepartment of Neurosurgery, Kings College Hospital, London, UK.
Ho-Keung NgDepartment of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China.
Xingang LiDepartment of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Jinan, China.
Kun MuDepartment of Pathology, Shandong University School of Medicine, Jinan, China.
Saoussen TrabelsiDepartment of Cytogenetics and Reproductive Biology, Farhat Hached Hospital, Sousse, Tunisia.
Dorra H'mida-Ben BrahimDepartment of Cytogenetics and Reproductive Biology, Farhat Hached Hospital, Sousse, Tunisia.
Alexei N KisljakovDepartment of Pathology, Morozov Children's Hospital, Moscow, Russian Federation.
Dmitry M KonovalovDepartment of Pathology, Dmitrii Rogachev Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
Andrew S MooreUQ Child Health Research Centre, The University of Queensland, Brisbane, Australia; Oncology Services Group, Children's Health Queensland Hospital and Health Service, Brisbane, Australia; The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia.
Angel Montero CarcabosoInstitut de Recerca Sant Joan de Deu, Barcelona, Spain.
Mariona SunolInstitut de Recerca Sant Joan de Deu, Barcelona, Spain.
Carmen de TorresInstitut de Recerca Sant Joan de Deu, Barcelona, Spain.
Ofelia CruzInstitut de Recerca Sant Joan de Deu, Barcelona, Spain.
Jaume MoraInstitut de Recerca Sant Joan de Deu, Barcelona, Spain.
Ludmila I ShatsDivision of Oncology, Pediatric Oncology and Radiotherapy, St Petersburg State Pediatric Medical University, St Petersburg, Russian Federation.
João N StavaleDepartment of Pathology, Federal University of São Paulo, São Paulo, São Paulo, Brazil.
Lucas T BidinottoMolecular Oncology Research Centre, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
Rui M ReisMolecular Oncology Research Centre, Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, Braga, Portugal and ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Natacha Entz-WerlePédiatrie Onco-Hématologie - Pédiatrie III, Centre Hospitalier Régional et Universitaire Hautepierre, Strasbourg, France.
Michael FarrellHistopathology Department, Beaumont Hospital, Dublin, Ireland.
Jane CryanHistopathology Department, Beaumont Hospital, Dublin, Ireland.
Darach CrimminsDepartment of Neurosurgery, Temple Street Children's University Hospital, Dublin, Ireland.
John CairdDepartment of Neurosurgery, Temple Street Children's University Hospital, Dublin, Ireland.
Jane PearsDepartment of Paediatric Oncology, Our Lady's Children's Hospital, Dublin, Ireland.
Michelle MonjeDepartment of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
Marie-Anne DebilyDépartement de Cancerologie de l'Enfant et de l'Adolescent, Institut Gustav Roussy, Villejuif, France.
David CastelDépartement de Cancerologie de l'Enfant et de l'Adolescent, Institut Gustav Roussy, Villejuif, France.
Jacques GrillDépartement de Cancerologie de l'Enfant et de l'Adolescent, Institut Gustav Roussy, Villejuif, France.
Cynthia HawkinsPediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Canada.
Hamid NikbakhtDepartment of Pediatrics, McGill University, Montreal, Canada.
Nada JabadoThe Center for Data Driven Discovery in Biomedicine (D(3)b), Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Suzanne J BakerDepartment of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN, USA.
Stefan M PfisterDivision of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany; Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.
David T W JonesDivision of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany.
Maryam FouladiDepartment of Pediatrics, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinnati, OH, USA.
André O von BuerenDepartment of Pediatrics, Division of Pediatric Hematology and Oncology, University Medical Center Goettingen, Goettingen, Germany; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University Hospital of Geneva, Geneva, Switzerland; Department of Pediatrics, CANSEARCH Research Laboratory, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Michael BaudisInstitute of Molecular Life Sciences, Swiss Institute of Bioinformatics, University of Zürich, Zürich, Switzerland.
Adam ResnickThe Center for Data Driven Discovery in Biomedicine (D(3)b), Children's Hospital of Philadelphia, Philadelphia, PA, USA; Division of Neurosurgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Chris JonesDivision of Molecular Pathology, The Institute of Cancer Research, London, UK; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK. Electronic address: chris.jones@icr.ac.uk.
Funding
The DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0MPrecision Medicine For Pediatric Low-Grade GliomasR01NS091620 · NINDS · DANA-FARBER CANCER INST · PI HAAS-KOGAN, DAPHNE A., RESNICK, ADAM CAIN · 2015 to 2019
$2.6MCooperating Pathways in GliomagenesisR01CA188516 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2014 to 2018
$1.9MPediatric low-grade gliomas: biology and molecular targeting.R01NS085336 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI RESNICK, ADAM CAIN · 2014 to 2018
$1.8MCancer Research UK 13982Cancer Research UK 23536Cancer Research UK C13468/A13982Cancer Research UK C13468/A23536NCI NIH HHS P01 CA096832NCI NIH HHS R01 CA188516NINDS NIH HHS R01 NS085336NINDS NIH HHS R01 NS091620
Abstract
We collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine glioma and 20 publicly available datasets in an integrated analysis of >1,000 cases. We identified co-segregating mutations in histone-mutant subgroups including loss of FBXW7 in H3.3G34R/V, TOP3A rearrangements in H3.3K27M, and BCOR mutations in H3.1K27M. Histone wild-type subgroups are refined by the presence of key oncogenic events or methylation profiles more closely resembling lower-grade tumors. Genomic aberrations increase with age, highlighting the infant population as biologically and clinically distinct. Uncommon pathway dysregulation is seen in small subsets of tumors, further defining the molecular diversity of the disease, opening up avenues for biological study and providing a basis for functionally defined future treatment stratification.
Indexed as
MutationAdolescentBrain Stem NeoplasmsCell Cycle ProteinsChildChild, PreschoolDNA Topoisomerases, Type IExomeF-Box ProteinsF-Box-WD Repeat-Containing Protein 7FemaleGene DosageGliomaHistonesHumansInfantBCOR protein, humanCell Cycle ProteinsDNA Topoisomerases, Type IF-Box ProteinsF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanHistonesProto-Oncogene ProteinsRepressor ProteinsUbiquitin-Protein LigasesDIPGexomegenomeglioblastomahistonemethylation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.